Welcome to our dedicated page for Boston Scientific Corporation news (Ticker: $BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Boston Scientific Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Boston Scientific Corporation's position in the market.
Rhea-AI Summary
Boston Scientific Corporation (BSX) announces a public offering of €750,000,000 and €1,250,000,000 aggregate principal amount of notes due 2029 and 2032 respectively. The offering is expected to close on February 27, 2024, to finance the acquisition of Axonics, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
-
Rhea-AI Summary
Boston Scientific employee Jackie MacDonald's health scare in 2010 leads to the discovery of a rare neurological disorder, highlighting the importance of early detection and treatment in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
-
Rhea-AI Summary
Boston Scientific launches new employee resource group, FIRE, to foster Indigenous resources and empowerment in honor of Native American Heritage Month. The group has over 350 members and aims to share hidden Native American histories and important truths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
Rhea-AI Summary
Boston Scientific Corporation (BSX) will participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024. Mike Mahoney, chairman and CEO, will have a 30-minute Q&A session. A live webcast will be available on the Investor Relations section of the Boston Scientific website. The replay will be available one hour after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Boston Scientific's Social Change Champions program aims to provide leadership opportunities for employees while making a sustainable impact in the health equity space. The company's recent pilot program involved 12 employees traveling to Lima, Peru, to help Socios en Salud, a recent Signature Health Grant recipient, with challenges such as defining a growth strategy and providing crucial HPV testing for cervical cancer. The program resulted in action plans to eliminate inefficiencies and boost revenue, as well as the creation of FAQs to educate women on the importance of cervical cancer screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
-
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the fourth quarter and full year 2023, with net sales of $3.725 billion and $14.240 billion, respectively. The company achieved significant growth in net sales, GAAP net income, and adjusted EPS compared to the prior year period. The CEO, Mike Mahoney, expressed gratitude towards the global team for the exceptional results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System, a new treatment for paroxysmal atrial fibrillation. The system uses non-thermal electric fields to ablate heart tissue, with positive clinical trial data and real-world use supporting its safety and efficacy. The system has also received Breakthrough Device Designation and CE Mark, with plans for immediate launch in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
-
Rhea-AI Summary
Axonics, Inc. (AXNX) Reports Strong Revenue Growth in Q4 and FY23, Expects 27% and 34% Increases Respectively. Preliminary unaudited revenue for Q4 2023 is $109.3 to $109.7 million, an increase of 27% compared to the prior year period. Fiscal Year 2023 revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022. The company attributes the growth to higher utilization and share of wallet at existing customers and the onboarding of new accounts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
-
Rhea-AI Summary
Axonics, Inc. (AXNX) has entered into a definitive agreement to be acquired by Boston Scientific Corporation (BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific Urology business and has pioneered significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and urethral bulking for women with stress urinary incontinence. The transaction is expected to close in the first half of 2024, pending approval of Axonics’ stockholders and receipt of required regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
Rhea-AI Summary
Boston Scientific Corporation (BSX) to acquire Axonics, Inc. (AXNX) for $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' products include the Axonics R20TM and the Axonics F15TM Systems for sacral neuromodulation therapy, with expected high revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
Boston Scientific Corporation
NYSE:BSX
BSX Rankings
BSX Stock Data
111.10B
1.46B
0.19%
93.66%
0.85%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
MARLBOROUGH
About BSX
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.